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period, as well as on the identification of the controversial 
issues which need further studies. There is general consen-
sus on the need of re-testing all isolated idiopathic GHD 
after at least 30-day withdrawn from treatment, while in 
patients with multiple pituitary deficiency and low IGF-I 
levels there is generally no need to re-test. In patients with 
permanent or confirmed GHD, a starting low rhGH dose 
(0.01–0.03 mg per day) to be adjusted according to IGF-I 
concentrations is also widely accepted. For those continu-
ing treatment, the optimal therapeutic schedule to obtain 
full somatic maturation, normalization of body composition 
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and bone density, cardiovascular function and Quality of Life, 
need to be evaluated.
Introduction
There is general agreement that GH treatment should be 
continued in patients with permanent growth hormone defi-
ciency (GHD) during the transition period between late 
puberty and complete psychophysical maturity (between 
15 and 25 years) after attainment of adult height [1]. These 
patients may in fact present body composition and meta-
bolic abnormalities related to their GHD as well as to other 
pituitary hormone deficiencies. Discontinuation of treat-
ment may lead to deterioration of metabolic profiles and 
reduction of bone mass [2–8]. However, there is still much 
controversy regarding a number of issues. The definition 
of the transition period [3, 9, 10] is a relatively new con-
cept and many physicians are not familiar with. The need 
to continue treatment, when and how to re-test, as well as 
the GH cut-off values to confirm the diagnosis of GHD 
is not well defined [11–14]. Furthermore, the dose of GH 
administration, how to monitor adherence to treatment, and 
its efficacy during the transition period, as related to both 
metabolic and body composition parameters, and Quality 
of Life (QoL) are still questioned [15–17]. In this regard 
it should be pointed out that the impact of GH replace-
ment during the transition period has not been adequately 
assessed in randomised clinical trials. Furthermore, no vali-
dated questionnaires are available to assess QoL in patients 
on GH replacement in the transition period.
Another important issue is related to the definition of 
who should be in charge for the management of the patient 
in the transition period, whether this requires a multidisci-
plinary approach or not [18], and how this multidiscipli-
nary approach would be defined and streamlined.
Current guidelines do not solve all the aforementioned 
controversial issues [3, 18–22]. This survey was carried 
out to investigate the current approach to the patient with 
GHD during the transition period among a number of Ital-
ian adult and paediatric endocrinologists.
Methods
Sixteen adult and paediatric endocrinologists from Italy 
were surveyed in a Delphi panel. The Delphi method is a 
structured communication technique, originally developed 
as a systematic, interactive forecasting method that relies 
on a panel of experts (Fig. 1). The experts answer question-
naires in two or more rounds. After each round, a facilitator 
provides an anonymous summary of the experts’ forecasts 
from the previous round as well as the reasons they pro-
vided for their judgments. Thus, experts are encouraged to 
revise their earlier answers in light of the replies of other 
members of their panel. It is believed that during this pro-
cess the range of the answers will decrease and the group 
will converge towards the “correct” answer [23, 24].
The Delphi methodology was chosen because it is 
a well-tested method for this type of process, and was 
applied according to a web-based approach designed to 
promote participation and a focus on quality (introduc-
tion of the issues to be addressed without constraints). A 
flow chart describing the process is illustrated in Fig. 1. 
The addressed issues included a definition of the transition 
period and diagnosis of GHD, withdrawal of treatment and 
re-testing, modalities of treatment, effects of treatment. The 
process was carried out in three stages, the first two on an 
individual basis and the third based on discussion and shar-
ing of opinions between participants.
Results
There was substantial agreement on the definition of the 
problems associated with the diagnosis and treatment of 
adolescents with GHD in the transition period, as well as 
the identification of the controversial and still less under-
stood issues which need further studies (see Table 1).
Definition of transition
The transition period refers to physical and psychoso-
cial changes, defined as starting in the late of puberty and 
ending with full complete maturation (3). This implies a 
“tempo” from mid to late teens until 6–7 years after the 
attainment of final height. Consequently, it is inappropriate 
to consider this phase as an extension of adolescence or an 
early aspect of adulthood [1].
Diagnosis
There is agreement that more research is needed on the 
diagnosis and treatment of GHD during the transition 
period focused to a better definition of diagnostic cut-
offs for the GH levels [1, 3, 11, 19]. Furthermore, there 
is no clear-cut definition of less severe GHD deficiency, 
which is only taken into account in some conditions (e.g., 
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post-operative status, irradiation, etc.), as well as on the 
effect of treatment. In these patients there is also general 
agreement that GHD should be confirmed by re-testing 
after withdrawn of treatment for 30 days at least. Longer 
intervals may be needed for reassessment of particu-
lar cases, due to the presence of other conditions and the 
ensuing need to verify the reversibility of some abnor-
malities (involving the heart, the bones, etc.). The pre-
ferred stimulation tests are ITT and GHRH + Arg. The 
currently accepted cut-off value for ITT is 6.1 μg/l (96 % 
sensitivity and 100 % specificity), and it is recognized that 
ITT may cause severe hypoglycaemia and is contraindi-
cated in patients with cardiac, neurological and adrenal 
diseases [25–28]. The currently accepted cut-off value 
for GHRH + Arg test is 19 μg/l (100 % sensitivity and 
97 % specificity) [13]. Side effects are minor, but the test 
has poor reproducibility and is not useful in patients with 
hypothalamic abnormalities (including irradiated patients). 
The GH response to this test is also markedly affected by 
the BMI, making it less useful in obese or overweight sub-
jects [13, 29]. The glucagon test is used in some centres, 
although it has never been validated in the transition period 
[30, 31].
According to current guidelines (3) and to the Italian 
Medicine Agency (AIFA), re-testing should not be per-
formed in patients with genetically GH deficiency (muta-
tions of the GH and GHRH genes) or multiple pituitary 
deficiencies with at least three hormonal deficits [idiopathic 
deficiency, genetic deficiency or deficiency associated with 
hypothalamic-pituitary abnormalities and IGF-I levels <−2 
standard deviation (SD) scores]. Some recommendations of 
current guidelines, not yet implemented by AIFA, should 
be considered, including the combined presence of a low 
IGF-I level and evaluation of the clinical context and of the 
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Fig. 1  The Delphi process. The first two stages were carried out on an individual basis and the third with the definition of the final document 
was based on a general discussion and sharing of opinions between participants
Table 1  Summary of the levels of agreement
Substantial agreement Partial agreement Agreement for future studies
Diagnosis, time of re-testing,  
re-testing modalities
Partial agreement between current practices  
and recommendations
Need to produce shared guidelines
 Questionnaire on QoL at the transition age,  
validated for Italy and EuropeGH dose, withdrawal from  
treatment
Definition of partial GH deficiency
 Definition of transition period and GHDIdentification of biochemical criteria to  
diagnose GHD during the transition period  Definition of non severe GHD (problems 
related to IGF-I assay and need to  
standardize)Monitoring of treatment by a multidisciplinary  team led by an endocrinologist
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risk/benefit ratio [32, 33]. In this regard it is recognized that 
treatment should result in IGF1 values of between 0 and +2 
SD, even though current assays are not entirely reliable [34]. 
Furthermore, evidence of deterioration of the metabolic pro-
file (lipid abnormalities), muscle mass and bone mass (by 
DEXA) and cardiac performance (Ultrasound evaluation of 
cardiac size and function) in untreated subjects should also 
be carefully taken into consideration [35–38].
Treatment
Treatment should be re-instituted in patients with con-
firmed GHD. The dose of GH should be tailored and 
titrated against IGF-I concentrations. The starting dose 
should be about half the dose recommended for children 
(0.01–0.03 mg/kg/day), but higher doses are used in some 
centres, and should be adjusted bimonthly based on IGF-I 
concentrations, which should be maintained between 0 and 
2 SDS [3, 39–41]. The dose should be lowered or treat-
ment should be discontinued in case of side effects such 
as arthralgia, headache, hyperglycaemia. According to the 
current evidence and guidelines, in female patients on oes-
trogen replacement therapy, the GH dose need to be aug-
mented or lowered depending on the route of oestrogen 
administration, i.e. oral or transdermal route [3, 42, 43].
Monitoring
Blood pressure, weight and waist circumference, lipid 
profile, IGF-I levels, serum glucose and HbA1c should 
be monitored every 6 months. Bone mineral density by 
DEXA, intima media thickness, specific QoL question-
naires should be evaluated every other year [44–50]. 
Besides IGF-I levels, the patient’s medical conditions, the 
level of adherence to treatment, as well as various fac-
tors, including BMI, gender and other replacement thera-
pies, should also guide in dose adjustment. In patients with 
additional pituitary hormone deficiencies, other parameters 
should be monitored related to the specific defects. These 
parameters include thyroid hormone measurement, serum 
electrolytes, and serum and urine osmolarity. It is expected 
that GH and other pituitary hormone replacement result in 
amelioration of biochemical, hormonal and body composi-
tion parameters.
It is recognized that the effects of GH treatment differ 
as a function of age and medical history of a patient with 
severe GHD. In young people with childhood onset GHD 
treatment aims at preventing alterations in muscle and bone 
function and in lipid profile. In subjects diagnosed in the 
transition period, replacement therapy aims at normalising 
the alterations that may already be present [39, 46, 49].
There is a general agreement that GH improves bone 
mass and bone metabolism, body composition, muscle 
strength and performance, intermediate metabolism, car-
diac and cardiovascular functions, and reproductive axis 
functioning, with positive effects on fertility [39, 46, 49, 
51, 52].
It is also recognized that all metabolic and body compo-
sition abnormalities may be due to GHD as well as to other 
pituitary hormone deficiencies. Therefore, attention to cor-
rect replacement therapy of all hormonal deficits is manda-
tory to obtain the expected benefits. Furthermore, careful 
reassessment of pituitary function at the end of the transi-
tion period is also needed.
Conclusions
This survey was carried out to investigate the current atti-
tude of adult and paediatric endocrinologists from Italy on 
growth hormone treatment of adolescents with GHD dur-
ing the transition period. The period from the adolescence 
through early adulthood is characterized by physical and 
psychological changes. Treatment is aimed at correct-
ing the GHD-associated abnormalities including reduced 
bone mineral density, muscle strength, lipid profile, glu-
cose metabolism and serum IGF-I levels. The results show 
that there is general consensus on the need of re-testing all 
isolated idiopathic GHD after at least 30-day withdrawn 
period. In patients with multiple pituitary deficiency and 
low IGF-I levels there is generally no need to re-test, since 
it has been repeatedly shown that these patients have per-
manent GHD [30].
There was no general agreement on the existence/
definition of partial (or less severe) GHD in the transi-
tion period. Also there was no general agreement on the 
need to continue treatment in adulthood in the absence of 
QoL data. The GH values of 6.1 and 19 μg/l after ITT and 
GHRH + Arginine, respectively, seem, up to date, the best 
cut-off limits although with some limitations linked to the 
effect of BMI on GH secretion and to the origin (pituitary 
or hypothalamic) of the defect. It is also widely accepted 
that GH treatment should be initiated with a low dose 
(0.2–0.5 mg per day) to be adjusted according to IGF-I 
concentrations. For those continuing treatment, the optimal 
therapeutic schedule to obtain full somatic maturation, nor-
malization of body composition and bone density, cardio-
vascular function and QoL, need to be carefully evaluated. 
General agreement has been reached on the need to con-
tinue research on the effect of treatment on body composi-
tion, bone metabolism, intermediate metabolism, and QoL.
In conclusion, this Delphi-based survey has allowed to 
confirm that Italian paediatric and adult endocrinologists 
do follow current guidelines in the diagnosis and treatment 
J Endocrinol Invest 
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of GHD patients in the transition period. The discussion 
did not bring to attention issues not previously considered 
in the literature, nor the need to adapt the current recom-
mendations to particular conditions.
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